Trial Profile
Ghrelin (OXE--103) for Acute Concussion Management
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Ghrelin (Primary)
- Indications Concussion
- Focus Therapeutic Use
- 30 May 2023 Status changed from recruiting to completed.
- 03 Aug 2022 According to an Oxeia Biopharmaceuticals media release, company announced the completion of an interim analysis of this trial, and full data results will be presented at a medical conference.
- 20 Oct 2020 Status changed from not yet recruiting to recruiting.